Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...

Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug ...

Shares of global pharma stocks slumped on Monday after President Trump vowed to cut drug prices for Americans by as much as 80%.

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

CRISPR ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...